Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and to the Greater Cambridge cluster in particular.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

Introduction to metabolomics analysis

This course which takes place at the European Bioinformatics Institute will provide an introduction to metabolomics through lectures and hands-on sessions, using publicly available data, software, and tools. Participants will become familiar with standardised workflows as well as with the current state of experimental design, data acquisition (LC-MS, MS imaging), processing, and modelling. In addition, they will learn about community standards and sharing in metabolomics, particularly through the use of EMBL-EBI’s MetaboLights repository and Galaxy infrastructure.

Business Analyst

Company Description:
PharmaVentures is a premier transaction advisory firm based in the London Area, United Kingdom, specializing in partnering, M&A deals, and strategic alliances for over 30 years. With expertise in licensing, mergers, acquisitions, and divestments, PharmaVentures provides comprehensive support for companies worldwide. The company is known for its deep insight into deal structures and successful partnering strategies.

New Government Delivers Optimism and Concern for the Region’s Life Sciences

By Tony Jones, CEO, One Nucleus

Recent weeks have been filled with varying degrees of anticipation and apprehension with regards to what UK government would start crystallising from grand election campaign gestures to actual measures and policies. After what felt like a long run of warnings of doom to the finally delivered ‘Invest 2025: the UK’s modern industrial strategy’ and ‘Autumn Budget 2024’.

NRG Therapeutics Selects First Development Candidate, NRG5051, and Secures Grant from The Michael J. Fox Foundation for Development of mPTP Inhibitors to Treat Neurodegenerative Diseases

• First development candidate selected, NRG5051, with potential to treat Parkinson’s and Amyotrophic Lateral Sclerosis (ALS) (also known as Motor Neuron Disease, MND) and other neurodegenerative diseases
• NRG5051 prevents mitochondrial dysfunction via inhibition of the mitochondrial permeability transition pore (mPTP) through a novel protein target
• Inhibition of the mPTP in the brain prevents neuronal cell death and reduces neuroinflammation in animals
• $5M grant from The Michael J. Fox Foundation (MJFF) to advance NRG5051 into the clinic

Subscribe to